Transgene Stock

TNG

FR0005175080

Biotechnology & Medical Research

Real-time Euronext Paris 06:18:30 2026-10-15 EDT			5-day change	1st Jan Change
0.6870 ^EUR	-0.43%		+0.29%	-28.44%

09-25	Transgene provides update on its operations
09-08	Transgene Expands ProBioGen Partnership With Additional License	MT

Last Transcript: Transgene

Transgene SA - Special Call

06-29

More transcripts

Analysts' recommendations: Transgene

06-25	Oddo BHF Stays Positive on Transgene
04-07	Transgene stands out following licensing agreement with NEC Bio
11-27	Oddo BHF Lowers Target Price on Transgene but Remains Upbeat
25-10-13	Transgene and BioInvent International AB Jointly Present a Poster on Transational Data and Updated Clinical Results from the Phase I Study of BT-001	CI
25-09-18	Transgene: analysts reiterate their recommendations after results

More recommendations

News in other languages: Transgene

10-05	Transgene présentera des données précliniques sur PoxSTG-EEV
10-05	Transgene présentera un poster sur les données précliniques de son virus oncolytique innovant au SITC 2026
10-01	Transgene participera à l’Investor Access
09-25	Bourse : les Arnault à la Maison Blanche, HelloFresh avertit et Meta 2000
09-25	Transgene fait le point sur son activité

More news

Managers and Directors: Transgene

Manager	Title	Age	Since
Alessandro Riva CEO	Chief Executive Officer	65	2023-05-31
Lucie Larguier DFI	Director of Finance/CFO	-	2024-03-26
Simone Steiner CTO	Chief Tech/Sci/R&D Officer	-	2025-04-01

Director	Title	Age	Since
Benoît Habert BRD	Director/Board Member	61	2010-07-26
Jean-Luc Bélingard BRD	Director/Board Member	77	2013-06-18
Alain Mérieux BRD	Director/Board Member	88	2006-12-31

More insiders

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

152

Sector

Biotechnology & Medical Research

Calendar

11-08 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-10-15	€0.6870	-0.43%	23,867
26-10-14	€0.6900	-0.43%	99,141
26-10-13	€0.6930	-0.43%	49,644
26-10-12	€0.6960	-0.57%	21,638
26-10-09	€0.7000	+2.19%	84,519

Real-time Euronext Paris

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6900EUR

Average target price

1.100EUR

Spread / Average Target

+59.42%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Transgene

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Transgene

Company calendar

Market Cap	189M 210M 176M 160M 300M 20B 302M 2.12B 826M 10.38B 789M 772M 33.39B	P/E 2026 *	-4.93x	P/E 2027 *	-3.14x
Enterprise Value	120M 133M 112M 101M 190M 12.68B 191M 1.34B 524M 6.58B 500M 489M 21.16B	EV / Sales 2026 *	16.6x	EV / Sales 2027 *	25.2x
Free-Float	19.11%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	TNG	Real-time
CBOE	TNGp	Real-time
OTC Markets	TRGNF	Delayed
Deutsche Boerse AG	TGNA	Delayed
CBOE	0OCQ	Real-time
Börse Stuttgart	TGNA	Delayed
Boerse Muenchen	TGNA	Real-time

09-25	Transgene provides update on its operations
09-08	Transgene Expands ProBioGen Partnership With Additional License	MT
09-03	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
09-02	Transgene: no cases of recurrence at three years among patients treated with TG4050
09-02	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
06-29	Transgene SA - Special Call
06-25	Oddo BHF Stays Positive on Transgene
06-25	Positive Preclinical Data for a Transgene Vaccine
06-25	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
06-22	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
06-22	Transgene launches a clinical trial evaluating TG4070 with nivolumab
06-22	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
05-22	Transgene SA Announces Board Appointments	CI

10-05	Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026	GL
10-01	Transgene to Participate in Investor Access	GL
10-01	Transgene to Participate in Investor Access	AQ
09-24	Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field	GL
09-24	2026 Half-Year Financial Report	GL

1 day	-0.43%
1 week	+0.29%
Current month	-4.85%
1 month	-20.21%
3 months	-7.16%
6 months	-11.01%
Current year	-28.44%

Transgene Stock

Stocks

TNG

FR0005175080

Biotechnology & Medical Research

Valuation: Transgene

Chart: Transgene

Latest news: Transgene

Last Transcript: Transgene

Analysts' recommendations: Transgene

Press Releases: Transgene

News in other languages: Transgene

Quotes and Performance

Price Extremes

Managers and Directors: Transgene

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 week	0.68	0.71
1 month	0.68	0.86
Current year	0.68	1.03
1 year	0.68	1.5
3 years	0.53	1.54
5 years	0.53	2.99
10 years	0.53	3.79

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	84,745,400	63.8367%
12/2/25	Compagnie Merieux Alliance SAS	Buy	Company	38,492,172	28.9953%
8/2/24	Compagnie Merieux Alliance SAS	Buy	Company	30,898,876	23.3562%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TRANSGENE	-0.43%	+0.29%	-47.95%	-50.65%	210M
WUXI APPTEC CO., LTD.	-2.01%	-7.86%	+60.74%	+70.97%	68.92B
ARGENX SE	+0.19%	+5.92%	+6.53%	+59.02%	51.9B
LONZA GROUP AG	+2.39%	+6.28%	+11.55%	+40.53%	48.73B
IQVIA HOLDINGS INC.	+0.51%	+1.51%	+27.96%	+31.43%	43.13B
REVOLUTION MEDICINES, INC.	+2.70%	-3.66%	+307.41%	+547.01%	41.48B
BEONE MEDICINES AG	+0.69%	-3.44%	+9.52%	+96.59%	39.96B
CELLTRION, INC.	+0.06%	-2.02%	+11.25%	+43.27%	30.6B
WUXI BIOLOGICS (CAYMAN) INC.	-2.21%	-10.09%	+35.34%	-0.73%	26.01B
BIONTECH SE	-0.39%	-6.92%	-13.60%	-14.40%	22.27B
Average	+0.14%	-4.36%	+40.87%	+82.30%	37.32B
Weighted average by Cap.	+0.22%	-4.28%	+54.59%	+103.98%

	2026 *	2027 *
Net sales	7.2M 8.01M 6.72M 6.09M 11.43M 762M 11.5M 80.64M 31.49M 396M 30.07M 29.41M 1.27B	7.2M 8.01M 6.72M 6.09M 11.43M 762M 11.5M 80.64M 31.49M 396M 30.07M 29.41M 1.27B
Net income	-38.2M -42.49M -35.65M -32.31M -60.66M -4.04B -61.04M -428M -167M -2.1B -160M -156M -6.75B	-61.6M -68.51M -57.49M -52.1M -97.82M -6.52B -98.43M -690M -269M -3.38B -257M -252M -10.88B
Net Debt	-69.2M -76.97M -64.58M -58.53M -110M -7.32B -111M -775M -303M -3.8B -289M -283M -12.23B	-7.7M -8.56M -7.19M -6.51M -12.23M -815M -12.3M -86.24M -33.67M -423M -32.15M -31.46M -1.36B